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Background: Limited data are available as to the relationship between computed tomography
(CT) derived data on emphysema and airway wall thickness, and quality of life in subjects with
chronic obstructive pulmonary disease (COPD). Such data may work to clarify the clinical
correlate of the CT findings.
Methods: We included 1778 COPD subjects aged 40e75 years with a smoking history of at
least 10 pack-years. They were examined with St George’s Respiratory Questionnaire
(SGRQ-C) and high-resolution chest CT. Level of emphysema was assessed as percent low-
attenuation areas less than 950 Hounsfield units (%LAA). Airway wall thickness was esti-
mated by calculating the square root of wall area of an imaginary airway with an internal
perimeter of 10 mm (Pi10).
Results: In both men and women, the mean total score and most of the subscores of SGRQ-C
increased with increasing level of emphysema and increasing level of airway wall thickness,
after adjusting for age, smoking status, pack years, body mass index and FEV1. The highest
gradient was seen in the relationship between the activity score and the emphysema level.
The activity score increased by 35% from the lowest to the highest emphysema tertile. The
relationship between level of emphysema and the total SGRQ-C score became weaker withof Radiology, University Medical Centre, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Tel.:
recht.nl (H.A. Gietema).
3 Elsevier Ltd. All rights reserved.
3.04.016
1202 H.A. Gietema et al.increasing GOLD (Global initiative for Chronic Obstructive Lung Disease) stages (p < 0.001),
while the impact of gender was limited.
Conclusion: In subjects with COPD, increasing levels of emphysema and airway wall thick-
ness are independently related to impaired quality of life.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is among
the leading causes of death worldwide and associated with
a substantial morbidity.1 COPD is characterized by airflow
limitation, which forms the basis for the diagnosis and
staging of the disease.2 However, it is widely acknowledged
that airflow limitation in terms of forced expiratory volume
in 1 s (FEV1) and forced vital capacity (FVC) does not
explain the whole picture of COPD.3
The functional abnormalities are known to be caused by
changes to the lung anatomy, and it is thought that small
airway remodeling and emphysematous destruction
contribute independently to the functional abnormalities.
Computed tomography (CT) of the chest offers the oppor-
tunity to divide the disease into anatomically based
phenotypes of disease, commonly referred to as emphyse-
matous or airway phenotypes.4 It is thought that a more
complete anatomic description of the lung will allow for the
possibility to study more specific COPD related genes and
biomarkers than when using spirometry alone.5,6
From a patient perspective the concept of airway wall
thickening and level of emphysema as measured by CT re-
mains abstract. A major concern to the patient is the level
of respiratory symptoms, particularly dyspnea, as well as
quality of life (QoL). While the relationship of respiratory
symptoms to CT findings has recently been examined,7,8
limited data are available as to how CT derived emphy-
sema level and airway wall thickness relate to QoL. In a
selective group of advanced COPD patients examined prior
to lung volume reduction surgery, lung transplantation or
resection for potential bronchogenic malignancy, Han et al.
found increased level of emphysema and airway wall
thickness related to impaired quality of life.9 In two other
studies comprising primarily men, increased level of
emphysema was also found to be associated to a worse
quality of life.10,11 A recent report from the COPDGene trial
found both level of emphysema and airway wall thickness
related to impaired QoL in terms of St George Respiratory
Questionnaire (SGRQ), with airway wall thickening being
more strongly related to QoL than extent of emphysema.12
To our knowledge, no data are available as to whether
the relationship between CT derived emphysema and
airway thickness and QoL differ by gender or whether the
CT-QoL relationships vary with severity of disease. Such
data may work to clarify the clinical correlate of the CT
findings and enhance the interpretation of chest CT in the
clinical setting.
We hypothesized that emphysema and airway wall
thickness are independently associated to impaired level of
QoL. To test this hypothesis, we used the “Evaluation Of
COPD Longitudinally To Identify Predictive Surrogate
Endpoints (ECLIPSE) Study (Clinicaltrials.gov identifierNCT00292552; GSK Study Code SCO104960). ECLIPSE
includes questionnaires, spirometry, exercise testing and
computed tomography (CT) scans from smokers suffering
from COPD, non-smoker controls and smoker controls with
no evidence of COPD which offers the opportunity to
examine to what extent CT findings explain QoL status
beyond that offered by spirometry. Finally, we aimed to
examine to what degree the CT-QoL relationship varies by
gender and disease status.
Methods
Participants
The population under study was the Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints
(ECLIPSE) cohort. The trial has been approved by the
relevant ethics and review boards at participating centers
and written informed consent was obtained from all par-
ticipants. A list of all participating centres can be found in
Appendix 2. The aims and operational aspects of the
ECLIPSE cohort have been described elsewhere.13 In-
dividuals aged 40e75 years were recruited to the study if
they had a smoking history of 10 pack-years, a post-
bronchodilator ratio between forced expiratory volume in
1 s (FEV1) and forced vital capacity (FVC) 0.7. In the
current analysis only COPD subjects were included, because
the SGRQ-c was developed to assess quality of life in COPD
subjects. Individuals recruited to the study were genotyped
for a1-antitrypsin deficiency and six PiZZ and 11 PiSZ
individuals were identified and also excluded from the
analysis.5
Pulmonary function testing
Pulmonary function testing (PFT) included post-
bronchodilator forced expiratory volume in one second as
percentage of predicted (FEV1%) and forced vital capacity
(FVC) with a pneumotachograph, performed following
American Thoracic Society (ATS) guidelines. Subjects were
asked to withhold bronchodilator medication for at least 6 h
prior to testing. COPD subjects were staged according to
the GOLD guidelines.14
Computed tomography
Computed tomography scans were acquired using
multidetector-row CT scanners (GE Healthcare or Siemens
Healthcare) with a minimum of 4 rows and obtained in su-
pine position, at suspended full inspiration without
administration of intravenous contrast. Exposure settings
were 120 kVp and 40 mAs and images were reconstructed at
Table 1 Characteristics of the study population.
Men Women p-Value
Number 1135 643
Age, (years) 63.8 (7.0) 62.4 (6.9) <0.001
Current
smoker (%)
36 38 0.455
Smoking,
pack-years
51.9 (28.5) 41.7 (21.2) <0.001
FEV1% predicted 47.0 (15.7) 50.8 (15.4) <0.001
GOLD Stage 2, % 40 50 <0.001
Stage 3, % 45 39
Stage 4, % 15 10
BMI (kg/m2) 26.7 (5.2) 25.8 (6.2) 0.003
%LAA 16.2 (8.8/26.4) 14.3 (6.0/24.4) <0.001
Pi10, mm 4.47 (0.18) 4.27 (0.16) <0.001
SGRQ-C Activity
score
62.8 (25.5) 66.1 (23.8) 0.010
SGRQ-C Impact
score
39.0 (22.1) 37.7 (22.1) 0.237
SGRQ-C
Symptoms score
60.8 (22.4) 58.5 (20.6) 0.035
SGRQ-C
Total score
50.0 (20.7) 50.0 (19.8) 0.951
CT lung volume
(ml)
6846 (1314) 5156 (900) <0.001
Inspiration level
(%)*
100.8 (18.2) 105.6 (17.0) <0.001
If not otherwise stated, the figures are mean (SD), FEV1, Forced
expiratory volume in one second, post bronchodilator value,
GOLD, Global initiative for Chronic obstructive lung disease.
BMI, Body mass index.
%LAA, Percent low-attenuation areas less than 950 HU, given
as median (25/75 percentile).
Pi10, Airway wall thickness at an internal perimeter of 10 mm
SGRQ-C, St George’s Respiratory Questionnaire.
* CT lung volume/TLC predicted.
CT parameters and quality of life in COPD 12031.0 mm (Siemens) or 1.25 mm (GE) contiguous slices, using
a low spatial frequency reconstruction algorithm (GE:
Standard, Siemens: b35f). CT scanners were calibrated
regularly and a standard CT phantom was scanned by all
participating centers to produce comparable data.
All CT scans were analyzed using Pulmonary Workstation
2.0 software (VIDA Diagnostics, Iowa City, IA). Briefly, the
lungs were segmented from the thorax wall, heart and main
pulmonary vessels, followed by segmentation of the indi-
vidual lobes. The airways were segmented using a region
growing algorithm starting in the trachea and projecting to
the smallest airway visible on the CT scan as previously
described.15,16 For this study, only third (“segmental”
based on the Boyden classification17 to fifth generation
airways were analyzed, since the number of segmented
airways dropped massively beyond the fifth generation.
We standardized airway wall area using the subject
specific regression equation between the square root of
Aaw of all included airways of that subject and their Pi to
calculate the square root of the wall area for an imaginary
airway with an internal perimeter of 10 mm (Pi10).18 By
applying this standardization, we adjusted for differences
in number of segmented airways and differences in loca-
tions of the segmented airways within the bronchial tree.
The extent of emphysema (% low attenuation areas, %
LAA) was estimated using the threshold technique quanti-
fying the percent of lung voxels with an apparent X-ray
attenuation value below 950HU.19
Quality of life
We used the St George’s Respiratory Questionnaire (SGRQ-
C) to determine the impact of COPD on quality of life.20
This is a supervised self-administered questionnaire
designed specifically for use in respiratory disease and
contains three domains: symptoms (relating to cough,
phlegm, wheezing and dyspnea); activity (relating to
physical activity limited by dyspnea); and impact (relating
to control, panic, medication and expectations). A total
score was calculated from all three domains. A subscore
was estimated for each domain.
Statistics
Proportions were tested via chi-squared tests; means were
compared by ANOVA and medians were compared by Krus-
kaleWallis tests. Normalized values were calculated as
(value-mean)/standard deviation (SD) in order to stan-
dardize 1 unit to 1 SD.
The associations between each of %LAA and Pi10 and the
components of the SGRQ-C questionnaire were examined
by multiple linear regression models with each of the SGRQ
total score and sub-scores as dependent variables. The
predictors of interest in the models were %LAA and Pi10
adjusted for age, smoking status, pack years, body mass
index (BMI), and FEV1. Analyses were stratified by sex and
by GOLD stage.
In order to compare the %LAA correlation coefficient to
that of Pi10, the linear regression analyses were performed
including both %LAA and Pi10 as predictors simultaneously.
%LAA and Pi10 were then also used as normalisedparameters, implying that one unit change corresponds to 1
SD change for that variable. Individual respiratory symp-
toms (the cough, phlegm and wheezing questions of the
SGRQ-C) and the relationship of Pi10 to each of the respi-
ratory symptoms were examined by multiple logistic
regression models with each symptom as dependent vari-
able and Pi10 as the independent variable adjusted for age,
smoking status, pack years, body mass index (BMI), and
FEV1.
P-values less than 0.05 were considered significant. All
analyses were performed with SAS Version 9.1 (SAS Insti-
tute Inc., Cary, NC, USA).
Results
In total 2161 COPD patients GOLD stage IIeIV were enrolled
in ECLIPSE; an additional 3 subjects were identified as
GOLD stage I. Of these participants, 386 (18%) were
excluded from the current analysis due to lack of suitable
CT scan or inability to calculate Pi10. Characteristics of the
study sample (n Z 1778 COPD cases) are shown in Table 1.
Women were slightly older, had less airflow limitation and a
1204 H.A. Gietema et al.lower BMI than men. In this population of COPD subjects,
there was a significant association between %LAA and FEV1%
predicted (r Z 0.49; p < 0.001), FEV1% was weakly
correlated to Pi10 (r Z 0.11; p < 0.001).CT derived parameters vs quality of life
Men and women were divided into tertiles by the extent of
emphysema and by airway wall thickness. Table 2 shows the
SGRQ-C total scores and subscores for each tertile.
The mean total score and almost all subscores of St
George’s Respiratory Questionnaire increased with
greater extent of emphysema in both men and women and
with increase in airway wall thickness in men. The
greatest increase was seen for the activity score,
increasing by about 35% from the lowest to the highest
emphysema tertile for both men and women. In women,
increasing airway wall thickness did not result in an in-
crease in SGRQ-C scores.
In the multiple linear regression analyses using non-
normalized data, the total SGRQ-C and also the subscores
were significantly correlated to the extent of emphysema.
This was observed in both men and women (Table 3A).
Results were adjusted for age, smoking status, pack years
and body mass index (BMI). Similar trends were noted for
the relationship between airway wall thickness levels and
the quality of life scores (Table 3A). The exception was the
relationship between activity score and Pi10 in women,
which did not vary significantly.
FEV1 percent predicted was then added to the regression
analyses. The coefficients for the relationships between
emphysema and quality of life scores were reduced, but
remained significant for the activity and the total scores in
men and for the total score in women. The coefficients
between airway wall thickness and the SGRQ-C scores
remained significant for the impact, symptoms and total
scores in both men and women (Table 3A).Table 2 Quality of life (in terms of St George respiratory questi
(%LAA) and level of airway wall thickness (Pi10).
Tertile Activity score Impac
Mean (SD) Mean
Men Level of Emphysema 1 54.4 (26.1) 37.2 (
2 61.4 (25.5) 37.1 (
3 72.7 (21.4) 42.6 (
p Value* <0.001 <0.00
Level of Airway
Wall Thickness
1 61.0 (24.6) 35.5 (
2 62.1 (27.5) 38.8 (
3 65.4 (24.3) 42.7 (
p Value* 0.052 <0.00
Women Level of Emphysema 1 54.8 (25.9) 34.5 (
2 67.6 (20.6) 39.2 (
3 75.9 (19.2) 39.4 (
p Value* <0.001 0.037
Level of Airway
Wall Thickness
1 69.3 (22.7) 36.9 (
2 61.2 (24.6) 34.4 (
3 67.7 (23.3) 41.7 (
p Value* 0.001 0.003We also performed multiple regression analysis stratified
by GOLD stage for the total SGRQ-C score and its domain
scores. %LAA was significantly associated with the total
score and the activity score in GOLD stages II and III, but not
in GOLD stage IV (Table E1). Additionally, %LAA was asso-
ciated with the symptoms score domain in GOLD stage II.
Pi10 was significantly associated with the total score and
the impact score in GOLD stages III and IV, but not in GOLD
II. There were no significant relationships observed be-
tween the impact score and %LAA or activity score and Pi10
in any GOLD stage.
Additional logistic regression analyses showed that
Pi10 was associated with all the respiratory symptoms
indicative of airway disease manifestation (cough,
phlegm, wheezing), after adjusting for gender, age,
smoking status, pack years, BMI and FEV1 percent pre-
dicted (Table 4).
Finally, level of emphysema and airway wall thickness
were added simultaneously to the linear regression equa-
tion in addition to gender, age, smoking status, pack years,
body mass index and FEV1 percent predicted (Table 3). Pi10
remained significantly related to all the SGRQ-C scores
except the activity score, while %LAA was still significantly
associated with the activity and total scores. The rela-
tionship between SGRQ-C total scores and extent of
emphysema was similar to the relationship between SGRQ-c
total scores and airway wall thickening. Activity scores
were only significantly related to %LAA and not to Pi10,
while impact score and symptoms scores were only signifi-
cantly related to Pi10.
In order to be able to compare the %LAA correlation
coefficient to those of Pi10, the analyses were repeated
with normalised parameters (Table 3). This analysis shows
that correlation coefficients for total scores are compara-
ble for %LAA and Pi10. Extent of emphysema is more
strongly associated to activity score, while impact score
and symptoms score are more strongly related to airway
wall thickening.onnaire (SGRQ-C)) In men and women by level of emphysema
t score Symptoms score Total score Lung volume (mL)
(SD) Mean (SD) Mean (SD) Mean (SD)
23.6) 59.2 (23.4) 46.2 (22.1) 5979 (1194)
21.4) 58.9 (22.7) 48.2 (20.6) 6688 (1182)
20.9) 64.3 (20.6) 55.6 (18.1) 7617 (1036)
1 0.001 <0.001 <0.001
20.8) 58.3 (21.1) 47.3 (19.4) 6906 (1259)
23.5) 60.9 (23.5) 49.7 (22.4) 6801 (1267)
21.4) 63.2 (22.4) 53.1 (19.9) 6572 (1415)
1 0.013 <0.001 0.002
24.5) 55.5 (23.1) 44.4 (22.3) 4635 (852)
21.2) 60.0 (19.9) 51.6 (18.2) 5172 (758)
20.2) 60.0 (18.2) 54.1 (17.0) 5564 (800)
0.035 <0.001 <0.001
20.9) 59.2 (18.9) 50.6 (18.1) 5096 (888)
21.6) 54.9 (21.4) 46.1 (20.4) 5256 (828)
23.3) 61.4 (20.9) 53.2 (20.1) 5017 (936)
0.004 0.001 0.018
Table 3 Multiple linear regression analyses of the relationship between level of emphysema and airway wall thickness, and
St George’s respiratory questionnaire (total and subscores) in subjects with COPD using unnormalised (upper part) and nor-
malised data (lower part) by gender (A) and for all subjects (B).
A Activity score Impact score Symptoms score Total score
Coefficient (SE) R2 Coefficient
(SE)
R2 Coefficient
(SE)
R2 Coefficient
(SE)
R2 p-Value
Men %LAA
Without FEV1%
Predicted
0.81
(0.06)**
0.13 0.28
(0.06)**
0.03 0.31
(0.06)**
0.06 0.45
(0.05)**
0.06
Including FEV1%
Predicted
0.40
(0.07)**
0.24 0.03
(0.06)
0.11 0.03
(0.06)
0.13 0.12
(0.06)*
0.18
Pi10
Without FEV1%
Predicted
14.83
(4.85)**
0.02 23.93
(4.15)**
0.03 15.68
(4.16)**
0.05 19.21
(3.93)**
0.03
Including FEV1%
Predicted
4.99
(4.35)
0.22 18.03
(3.98)**
0.13 9.91
(4.01)*
0.13 12.34
(3.63)**
0.19
Women %LAA
Without FEV1%
Predicted
0.72
(0.08)**
0.16 0.20
(0.08)*
0.03 0.22
(0.07)**
0.05 0.36
(0.07)**
0.06
Including FEV1%
Predicted
0.35
(0.08)**
0.27 0.06
(0.09)
0.09 0.02
(0.08)
0.09 0.08
(0.07)
0.15
Pi10
Without FEV1%
Predicted
2.18
(6.47)
0.05 18.21
(6.11)**
0.03 11.10
(5.64)*
0.04 11.17
(5.51)*
0.02
Including FEV1%
Predicted
1.99
(5.75)
0.25 18.15
(5.89)**
0.10 11.43
(5.48)*
0.09 11.39
(5.13)*
0.16
Activity score Impact score Symptoms score Total score
Coefficient
(SE)
R2 Coefficient
(SE)
R2 Coefficient
(SE)
R2 Coefficient
(SE)
R2
Men %LAAa 0.42
(0.07)**
0.25 0.02
(0.06)
0.13 0.06
(0.06)
0.13 0.15
(0.06)*
0.19
Pi10$$ 8.86
(4.33)*
0.25 18.18
(4.02)**
0.13 10.43
(4.06)*
0.13 13.71
(3.66)**
0.19
Women %LAA$ 0.36
(0.08)**
0.27 0.01
(0.09)
0.10 0.05
(0.08)
0.09 0.12
(0.08)
0.16
Pi10$$ 2.40
(5.77)
0.27 18.03
(5.99)**
0.10 12.00
(5.56)*
0.09 12.82
(5.21)*
0.16
B Activity score
coefficient (SE)
Impact score
coefficient (SE)
Symptoms score
coefficient (SE)
Total score
coefficient (SE)
%LAA
Without FEV1% predicted 9.35 (0.62)** 3.22 (0.58)** 3.52 (0.56)** 5.15 (0.53)**
Including FEV1% predicted 4.62 (0.66)** 0.39 (0.63) 0.24 (0.62) 1.25 (0.56)*
Pi10
Without FEV1% predicted 0.21 (0.66) 3.41 (0.58)** 2.65 (0.57)** 2.30 (0.54)**
Including FEV1% predicted 1.49 (0.59)* 2.44 (0.56)** 1.72 (0.55)** 1.11 (0.50)*
Activity score
coefficient (SE)
Impact score
coefficient (SE)
Symptoms score
coefficient (SE)
Total score
coefficient (SE)
%LAAb 4.48 (0.66)** 0.04 (0.64) 0.49 (0.62) 1.43 (0.57)*
Pi10c 0.99 (0.59) 2.43 (0.57)** 1.78 (0.55)** 1.27 (0.50)*
%LAA, Percent low-attenuation areas less than 950 HU.
Pi10, Airway wall thickness at an internal perimeter of 10 mm.
*p < 0.05.
**p < 0.01.
a Adjusted for age, smoking status, pack years, and body mass index.
b Adjusted for gender, age, smoking status, pack years, and body mass index, FEV1 % predicted and Pi10.
c Adjusted for gender, age, smoking status, pack years, and body mass index, FEV1 % predicted and %LAA.
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1206 H.A. Gietema et al.Discussion
In this large population of COPD cases, we have shown that
both the extent of emphysema and airway wall thickness
are significantly related to impaired quality of life
measured using the SRGQ-C total scores. Airway wall
thickness was also independently related to the impact and
symptoms scores while emphysema was significantly asso-
ciated to the activity score.
This study confirms previous observations in selected
COPD subjects that emphysema and airway wall thickness
are related to quality of life.9e12 Furthermore, the current
study expands previous results by showing that these re-
lationships are present in both men and women. For
emphysema the relationship decreases with increasing
severity of COPD, while the correlation between Pi10 and
SGRQ-C became stronger with increasing GOLD stage.
The relationship between emphysema and the activity
score was clearly stronger than the relationship between
emphysema and the symptoms score (Table 3). This is in
line with recent findings from the COPDGene cohort.12
The reported effect can be due to the fact that COPD pa-
tients reduce their activity as the disease progresses and
thereby experience relatively reduced level of dyspnea.21
Hence, asking the patients about level of dyspnea may
not capture the disease severity to the same extent as
asking them about activity level. If this is true, our findings
indicate that the recently reported relationship between
CT derived level of emphysema and dyspnea might be
underestimated.7 Airway wall thickening was more strongly
related to impact and symptoms scores, while emphysema
was not. This is not surprising since cough and phlegm
symptoms were reported to be related to airway wall
thickness, but not to emphysema.7 We also reported
significant associations between Pi10 and respiratory
symptoms.
The relationship between the CT derived extent of
emphysema and airway wall thickness and activity scores
may be partly explained by dyspnea on exertion. However,
the impaired activity in COPD could also be due to muscle
atrophy, osteoporosis, cardiac co-morbidities and general
fatigue all of which may be related to emphysema.22,23
The CT indices of both emphysema and airway remod-
elling were related to the impact score, but after adjusting
for FEV1 percent predicted, only the association between
airway wall thickness and the impact score remained sig-
nificant (Table 3). This may indicate that the psychosocial
impact of COPD is at least partly reflected by the extent of
airflow limitation which is more strongly related to
emphysema than to airway wall thickness.24
The relationships between the extent of emphysema and
the total score and all the subscores of SGRQ-C became
weaker with increasing GOLD stage. This indicates that
aspects other than emphysema become more important to
QoL as the disease progresses, also reflected by the cor-
relation coefficients for the association between Pi10 and
total scores that increased with increasing GOLD stage.
The decline in the relationship between emphysema and
QoL relationship with increasing disease severity may partly
be explained methodologically as SGRQ-C was developed in
COPD subjects not housebound.20 Hence, the SGRQ-C may
CT parameters and quality of life in COPD 1207reflect QoL more poorly in patients with end stage disease
as compared to less severe stages.
Men and women did not differ in their SGRQ-C total
scores despite the fact that men had a slightly worse FEV1%
predicted, but we reported that activity scores for women
are greater than for men, while symptoms scores were
greater for men. It is worth noticing that although the level
of emphysema was greater in men than women with similar
SGRQ-C scores, the emphysema-QoL relationships did not
differ by gender. This implies that the relative contribution
of emphysema to the QoL differs in men and women.
For the current study CT emphysema was defined as
areas with an attenuation below 950 HU. Although Madani
et al. have suggested that for multislice imaging the cor-
relation between extent of low attenuation areas and
extent of emphysema at histology is strongest for a
threshold of 960 HU,25 the threshold of 950 HU is still
widely used, including the study by Martinez et al.12 By
using the 950 HU threshold, our results are easier to
compare the results from other studies.
This paper has several strengths. It is based on a large
COPD cohort, allowing for subgroup analyses that have not
been possible in previous studies on this topic. Further-
more, the subjects were recruited from 46 centres covering
populations in Europe and North America and although the
sample is not a true population sample, the study cohort
includes subjects that comprise the majority of clinical
relevant cases in the COPD population at large (GOLD stage
2 and 3).25 Finally, QoL was assessed by SGRQ-C which has
been extensively validated in COPD subjects.26
Some limitations should also be acknowledged. The
measurement of airways was performed by segmenting the
airway tree as far as possible on the CT scans. As a result,
only airways that can be segmented by the software are
measured and these are mainly large airways. It is possible
that airways that are severely affected by inflammation
and show serious lumen narrowing cannot be segmented
and therefore cannot be analyzed. However, Nakano et al.
have shown that wall thickness of the large airways is a
good surrogate for wall thickness of small airways18 and
numerous studies have shown that measurements of these
medium sized airways correlate with lung function.27
Studies have also shown that the number of airways seen
on CT is lower in subjects with COPD than in smoker con-
trols.28 Moreover, McDonough has shown that the drop in
airway number seen using CT is reflective of the drop in the
small airway number count using detailed micro-CT29 and
that the airways that are remaining are thicker than in
control subjects.29,30 Another surrogate for small airways
disease is thought to be the presence of air trapping on
expiratory CTs.31 Unfortunately, while this would provide
useful data, expiratory CTs were not performed in ECLIPSE
and we are unable to comment on air trapping. Therefore,
while it is likely that we underestimated the severity of
airway disease in COPD subjects by the inability to segment
the small and severely affected airways we believe that our
findings are indicative of the anatomic changes to airway
size and number in COPD.
The CT scans were not spirometrically gated. However,
it has been shown that the repeatability of quantitative
CT tests is high and not likely to improve by using spiro-
metric gating.32 We also performed the analyses with CTparameters corrected for inflation level using the ratio of
the CT derived lung volume to the lung volume measured by
plethysmography. Adding this ratio to the equations made
only small, non significant changes to the reported co-
efficients (data not shown).
Another limitation is that the extent of emphysema is
represented as the percentage of the lung showing low X-
ray attenuation. However, level of inspiration during the
scan, cardiac congestion, fibrosis and increased phlegm
production will reduce %LAA, while image noise can in-
crease the level of %LAA thereby influencing the specificity
of %LAA as an indicator of emphysema. Finally, this analysis
is cross-sectional in design and conclusions about how
changes in anatomy affect changes in the SGRQ-C scores
cannot be assessed from this study.
Conclusion
COPD is a complex disease with symptoms that extend
beyond simple airflow limitation, as measured by FEV1, into
other spectrums including their quality of life. The data
from the current study show that both lung parenchyma
and airway wall measurements obtained using quantitative
CT scans provides information on the anatomic changes
that are causing the functional and quality of life changes
seen in COPD. These techniques may be useful to sub-divide
patients into specific groups for testing of hypothesis
related to pathogenesis of disease and for testing novel
therapeutics.
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